# [18F]ACI-19626 PET in TDP-43 Proteinopathies

> **NCT06891716** · EARLY_PHASE1 · RECRUITING · sponsor: **AC Immune SA** · enrollment: 45 (estimated)

## Conditions studied

- Frontotemporal Dementia (FTD)
- Amyotrophic Lateral Sclerosis (ALS)
- TDP-43 Proteinopathies
- Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Alzheimer's Disease (AD)

## Interventions

- **OTHER:** [18F]ACI-19626

## Key facts

- **NCT ID:** NCT06891716
- **Lead sponsor:** AC Immune SA
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-21
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891716, "[18F]ACI-19626 PET in TDP-43 Proteinopathies". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06891716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*